Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure

Anis Hanna 1 · Nikolaos G. Frangogiannis 1

Accepted: 1 September 2020 / Published online: 9 September 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract
Heart failure exhibits remarkable pathophysiologic heterogeneity. A large body of evidence suggests that regardless of the underlying etiology, heart failure is associated with induction of cytokines and chemokines that may contribute to the pathogenesis of adverse remodeling, and systolic and diastolic dysfunction. The pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6 have been extensively implicated in the pathogenesis of heart failure. Inflammatory cytokines modulate phenotype and function of all myocardial cells, suppressing contractile function in cardiomyocytes, inducing inflammatory activation in macrophages, stimulating microvascular inflammation and dysfunction, and promoting a matrix-degrading phenotype in fibroblasts. Moreover, cytokine-induced growth factor synthesis may exert chronic fibrogenic actions contributing to the pathogenesis of heart failure with preserved ejection fraction (HFpEF). In addition to their role in adverse cardiac remodeling, some inflammatory cytokines may also exert protective actions on cardiomyocytes under conditions of stress. Chemokines, such as CCL2, are also upregulated in failing hearts and may stimulate recruitment of pro-inflammatory leukocytes, promoting myocardial injury, fibrotic remodeling, and dysfunction. Although experimental evidence suggests that cytokine and chemokine targeting may hold therapeutic promise in heart failure, clinical translation remains challenging. This review manuscript summarizes our knowledge on the role of TNF-α, IL-1, IL-6, and CCL2 in the pathogenesis of heart failure, and discusses the promises and challenges of targeted anti-cytokine therapy. Dissection of protective and maladaptive cellular actions of cytokines in the failing heart, and identification of patient subsets with overactive or dysregulated myocardial inflammatory responses are required for design of successful therapeutic approaches.

Keywords Heart failure · Cytokine · Chemokine · Inflammation · Interleukin-1 · TNF-α

Introduction
Heart failure is a condition in which the heart either cannot pump enough blood to meet the needs of various tissues or can do so only at the cost of increased filling pressures [1, 2]. Based on the ejection fraction, the most commonly used indicator of systolic function, heart failure patients can be classified into two major groups. Heart failure patients with reduced ejection fraction (HFrEF) exhibit depressed systolic function. On the other hand, the term heart failure with preserved ejection fraction (HFpEF) is used for patients who have the same heart failure symptoms, in the absence of significant reductions in ejection fraction. Elevated filling pressures in HFpEF patients are caused predominantly by perturbations in diastolic function. Epidemiologic studies have demonstrated that HFpEF accounts for almost half of all incident heart failure [3]. Both HFrEF and HFpEF have a poor prognosis. Although approaches targeting neurohumoral pathways have shown beneficial effects in patients with HFrEF, effective therapeutic strategies for HFpEF are lacking.

A major obstacle that hampers development of new therapeutics in heart failure is the pathophysiologic heterogeneity of the disease. The clinical syndrome of heart failure can be triggered by a wide range of pathophysiologic changes, including myocardial ischemia and infarction, pressure or volume overload, metabolic dysregulation, genetic perturbations in sarcomeric protein function, and responses to viral infections. Regardless of underlying etiology, heart failure is
associated with both local and systemic activation of inflammatory signaling cascades [4]. In patients with myocarditis or inflammatory cardiomyopathies, inflammation is the primary cause of heart failure [5]. Moreover, cytokine-mediated inflammation has been implicated in acute stress-induced cardiomyopathy [6], an enigmatic entity that may be associated with major emotional or physical stress [7], and may also be a rare cause of myocardial injury in patients with coronavirus disease 2019 (COVID-19) [8, 9]. In most other cases, activation of an inflammatory program reflects a reparative or protective response to other primary injurious processes. Regardless of the underlying etiology, excessive, unrestrained, or dysregulated inflammation may exacerbate myocardial injury, thus contributing to the progression of heart failure. The inflammatory response in the failing heart is characterized by induction and activation of a wide range of pleiotropic cytokines and chemokines that modulate phenotype and function of all myocardial cells. The complexity and pleiotropy of inflammatory mediators have hampered therapeutic implementation of therapeutic strategies targeting the inflammatory response.

This review manuscript discusses the potential role of the best-studied and most promising pro-inflammatory cytokines and chemokines as therapeutic targets in heart failure. We focus on the prototypic inflammatory cytokines tumor necrosis factor (TNF-α), interleukin (IL)-1 and IL-6, and on the CC chemokine CCL2/monocyte chemoattractant protein (MCP)-1. We summarize the cell biological actions of these mediators in the failing heart and their potential contribution to dysfunction and heart failure progression. Finally, we discuss the promises and challenges of cytokine and chemokine targeting in heart failure patients.

**Inflammatory Cytokines in the Pathogenesis of Chronic Heart Failure**

A large body of evidence, derived through both experimental and clinical studies, supports an important role for inflammatory cytokines and chemokines in the pathogenesis of myocardial dysfunction and adverse cardiac remodeling. Marked elevations of circulating pro-inflammatory cytokines are consistently noted in heart failure patients, in both HFrEF and HFpEF subpopulations [10, 11]. Cytokine levels are further increased in patients exhibiting an acute decompensation [12] and seem to predict clinical outcome [13]. Patients with ischemic cardiomyopathy in the absence of myocardial infarction exhibit induction of chemokines in chronically ischemic myocardial segments, accompanied by recruitment of inflammatory leukocytes [14]. Moreover, several studies using experimental animal models of heart failure induced through a wide range of pathophysiologic perturbations showed that disruption of pro-inflammatory cytokine signaling may exert beneficial actions [15–17]. However, this evidence should not be interpreted as suggestive of unidimensional deleterious effects of inflammatory cytokine signaling in failing hearts. Inflammatory cytokines are highly pleiotropic and multifunctional. Several members of the cytokine and chemokine families are upregulated in response to myocardial injury and may exert important protective actions on cardiomyocytes [18], while activating reparative programs [19]. Although there is little doubt that dysregulated, excessive, or prolonged inflammatory responses precipitate or worsen heart failure in human patients, the relative contribution of inflammatory signaling likely depends on the underlying etiology of the disease. In patients developing heart failure due to viral myocarditis, inflammatory injury may be the primary cause of dysfunction and adverse remodeling [5, 20]. In contrast, in other heart failure etiologies, the role of inflammatory cytokines is less convincingly documented. All types of myocardial injury result in secondary activation of an immune response. Several lines of evidence support the notion that regardless of the underlying etiology of heart failure, cytokine and chemokine induction promote dysfunction and progressive remodeling of the myocardium. First, inflammatory cytokines have negative inotropic effects [21]. Second, inflammatory cytokines may promote cardiomyocyte apoptosis [22]. Third, pro-inflammatory cytokines may activate a matrix-degrading program, inducing matrix metalloproteinases, and triggering extracellular matrix degradation [23], thus depriving cardiomyocytes from key matrix-driven signals that preserve homeostatic function. Fourth, chronic pro-inflammatory cytokine activation may stimulate a fibrogenic program, leading to induction of fibrogenic growth factors, expansion of activated fibroblasts, and subsequent deposition of extracellular matrix (ECM) proteins in the cardiac interstitium. Inflammation-mediated interstitial fibrosis may increase myocardial stiffness, contributing to the pathogenesis of HFpEF [24, 25]. To what extent these detrimental actions outweigh any protective effects of the inflammatory mediators is dependent on the pathophysiologic context and on the cytokine-specific patterns of inflammatory activation.

**Pro-Inflammatory Cytokines in Heart Failure**

**TNF-α**

The multifunctional cytokine TNF-α is the best-studied inflammatory mediator in heart failure. In the early 1990s, observations suggesting that HFrEF patients have markedly elevated circulating TNF-α levels [10] triggered a large body of experimental work to investigate the effects of TNF-α in the failing heart. Although clinical trials showed that anti-TNF approaches do not benefit human heart failure patients, the insights gained by studying the role of TNF-α in the
myocardium contributed significantly to our understanding of the complex role of inflammation in heart disease, and the clinical investigations highlighted the challenges of therapeutic translation.

Expression and Role of TNF-α in Heart Failure

Increased myocardial expression of TNF-α has been consistently documented in experimental models of heart failure [26, 27] and in human patients with cardiomyopathic conditions [28]. Several different cell types contribute to the increased expression of TNF-α in injured and failing hearts, including cardiomyocytes [27], macrophages [29], vascular cells [29], and mast cells [30]. The mechanisms of TNF-α induction may involve activation of mechanosensitive signaling cascades [27], neurohumoral signaling, or responses to damage-associated molecular patterns (DAMPs) released by injured cardiomyocytes. Several lines of evidence support the notion that TNF-α may play a causative role in heart failure. First, mice with cardiac-specific overexpression of TNF-α develop dilated cardiomyopathy [22, 31, 32] and infusion of TNF-α impairs LV systolic and diastolic function in dogs [33]. Second, TNF deletion attenuated dysfunction in a model of left ventricular pressure overload [15], and TNF-α antagonism reduced adverse remodeling and improved hemodynamics in models of volume overload and post-infarction heart failure [34, 35]. Third, in human heart failure patients, higher circulating levels of TNF-α were associated with increased mortality rates in both HFrEF and HfPEF subpopulations [36].

Cell Biological Mechanisms Responsible for the Effects of TNF-α in Heart Failure

TNF-α-mediated adverse remodeling and heart failure progression may involve effects on cardiomyocytes, macrophages, and the extracellular matrix (Fig. 1). In cardiomyocytes, TNF-α exerts negative inotropic actions by perturbing calcium homeostasis [37] and may trigger an apoptotic response by activating intrinsic cell death pathways [38]. In macrophages, TNF-α may stimulate synthesis of other pro-inflammatory cytokines with pro-apoptotic, negative inotropic, and matrix-degrading properties [39], and may upregulate expression of inducible nitric oxide synthase (iNOS) [40]. In fibroblasts, TNF-α may disrupt the balance between matrix metalloproteinases (MMPs) and their inhibitors, leading to ECM degradation [41, 42]. Finally, in the microvasculature, TNF-α increases permeability through modulation of endothelial cyclooxygenase-2, [43] and induces expression of endothelial adhesion molecules, such as intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 [44], thus enhancing adhesive interactions between circulating leukocytes and the endothelial lining. Neutrophils or pro-inflammatory monocytes may be trapped in the cardiac microcirculation, thus contributing to tissue injury and cardiac dysfunction.

Several studies have suggested that in addition to its effects in progression and accentuation of adverse remodeling and dysfunction, TNF-α may also exert protective actions on injured or stressed cardiomyocytes. In a model of non-reperfused MI, global deletion of TNF receptors (TNFRs) was associated with increased infarct size, suggesting that TNF-α signaling may transduce cytoprotective signals [18]. In a genetic model of cardiomyopathy due to desmin loss, TNF-α was found to have cytoprotective actions by promoting formation of an alternative cytoskeletal network that prevents deterioration of cardiac function [45]. Whether this mechanism can be generalized in other models of heart failure remains unknown. In isolated rat hearts, low-dose TNF-α improved hemodynamics; the favorable actions were attributed to the inhibitory effect of TNF-α on cardiomyocyte calcium influx that may have reduced intracellular calcium overload [46]. In addition, TNF-α protected mitochondrial respiratory function following anoxia/reoxygenation injury presumably due to modulation of reactive oxygen species (ROS) and sphingolipids [47]. The conflicting findings suggesting both protective and injurious effects of TNF-α in vivo may reflect dose-dependent effects or differences in the balance between TNFR1 versus TNFR2 signaling in various cell types and experimental models. It has been suggested that the deleterious effects of TNF-α on cardiac remodeling may be mediated through TNFR1 signaling; in contrast, TNFR2 actions may be beneficial [39]. However, the cell-specific actions of TNFR signaling in vivo and their role in mediating cardiac remodeling have not been systematically investigated.

TNF-α Antagonism in Patients with Heart Failure

The in vivo evidence on the deleterious effects of TNF-α in the failing myocardium, and early clinical studies suggesting attenuated dysfunction in small groups of patients receiving TNF-α antagonists [48] fueled large clinical trials to investigate the effectiveness of TNF-α blockade in HFrEF patients. Unfortunately, the results were disappointing [49]. The Randomized Etanercept North American Strategy to Study Antagonism of CytokinEs (RENAISSANCE) and Research into Etanercept Cytokine antagonism in Ventricular dysfunction (RECOVER) trials tested the effects of TNF-α antagonism through administration of soluble TNFR (etanercept) in patients with heart failure and systolic dysfunction. Both trials were halted prematurely due to the lack of clinical benefit. In addition, the data from both trials were combined in the Randomized Etanercept Worldwide Evaluation (RENEWAL) trial; however, again etanercept had no effect on the primary endpoint of death or heart failure hospitalization in HFrEF patients [50]. The phase II Anti-TNF-α in Congestive Heart Failure (ATTACH) trial examined the effects of infliximab, a chimeric monoclonal anti-TNF-α antibody in HFrEF patients. TNF-α antagonism using
infliximab had adverse effects, increasing all-cause mortality and heart failure hospitalizations in comparison with conventional treatment [51]. The conflicting findings between the highly promising animal model investigations and early clinical studies, and the disappointing large clinical trials are frustrating, but may be explained considering the heterogeneity of heart failure and the pleiotropic effects of the cytokines. First, in human patients the (well-described) protective effects of TNF-α on cardiomyocytes may be more prominent than any deleterious actions. Second, human heart failure populations are pathophysiologically heterogeneous. Thus, TNF-α antagonism may afford benefit in a yet unidentified subset of patients with prominent cytokine-mediated injury. Third, dose-dependent effects of the cytokine may complicate design of effective therapy. Failing hearts may require an optimal level of TNF-α activity to preserve function and to prevent excessive remodeling. In addition, intrinsic biological actions of the anti-TNF agents may have contributed to the adverse effects of the treatment in some clinical trials. TNFR antagonists may also act as agonists (referred to as “stimulating antagonists”) and may stabilize the cytokine under certain conditions [52].

Expression and Role of IL-1 in Heart Failure

IL-1

The IL-1 family has 11 cytokine members and 10 receptors [53]; IL-1α/IL-1β, IL-18, and the IL-33/ST2 axis are the best-studied members of the family in the cardiovascular system. A large body of experimental evidence supports the notion that members of the IL-1 family may play an important role in progression of heart failure and in the pathogenesis of systolic dysfunction [54, 55]. However, the potential effectiveness of IL-1 targeting in patients with heart failure has not been established.

IL-1

The IL-1 family has 11 cytokine members and 10 receptors [53]; IL-1α/IL-1β, IL-18, and the IL-33/ST2 axis are the best-studied members of the family in the cardiovascular system. A large body of experimental evidence supports the notion that members of the IL-1 family may play an important role in progression of heart failure and in the pathogenesis of systolic dysfunction [54, 55]. However, the potential effectiveness of IL-1 targeting in patients with heart failure has not been established.

Expression and Role of IL-1 in Heart Failure

IL-1 is consistently upregulated in experimental models of heart failure due to a wide range of etiologies, including myocardial infarction [56], left ventricular pressure overload [57, 58], transgenic overexpression of calcineurin [59], and diabetic cardiomyopathy [60]. Moreover, myocardial IL-1β induction has been reported in patients with cardiomyopathic conditions [61]. Heart failure is also associated with activation of
the inflammasome [62], a molecular platform of several components that is involved in caspase-1-mediated processing of pro-IL-1β into its active form. Several cell types may contribute to IL-1 synthesis and activation in injured and failing hearts, including immune cells, fibroblasts, vascular cells, and cardiomyocytes [57, 62–64].

Extensive experimental evidence suggests an important role for IL-1 signaling in the pathogenesis of cardiac dysfunction and adverse remodeling associated with heart failure. Mice with genetic disruption of IL-1 signaling due to loss of IL1RI, the signaling receptor for IL-1, had attenuated adverse remodeling after myocardial infarction, exhibiting suppressed inflammatory responses [16]. Pharmacologic targeting of IL-1 cascades also showed protective effects in experimental models. Administration of recombinant IL-1Ra (anakinra) protected the heart from adverse remodeling in rodent models of post-infarction and non-ischemic heart failure [65, 66]. Treatment with anti-IL-1β antibodies was also effective in heart failure models. In both diabetic and non-diabetic rats with post-infarction heart failure, administration of the anti-IL-1β antibody gevokizumab attenuated dilative remodeling and improved ventricular function, reducing hypertrophy and fibrosis [67]. However, some studies have suggested that endogenous activation of sub-inflammatory levels of IL-1β may also play an adaptive role following pressure overload mediating growth factor-induced compensatory hypertrophy [68].

What Are the Cellular Mechanisms of IL-1-Mediated Heart Failure?

As the prototypical pleiotropic pro-inflammatory cytokine, IL-1 acts on many different cell types (Fig. 1). Although the cellular basis for IL-1-driven cardiac remodeling and dysfunction has not been systematically studied, associative data and in vitro experiments suggest several potential mechanisms. First, much like TNF-α, IL-1 suppresses systolic cardiomyocyte function through effects that may involve disruption of calcium handling [69] or suppression of β-adrenergic responses [70]. Second, IL-1 exerts pro-apoptotic actions on cardiomyocytes [71]. Third, IL-1 induces leukocyte mobilization and activation, thus stimulating downstream inflammatory responses [72, 73]. Fourth, IL-1 may stimulate adhesion molecule expression in endothelial cells [74], promoting adhesive interactions with circulating leukocytes and increasing recruitment of inflammatory cells in the myocardium. Fifth, IL-1 promotes a matrix-degrading phenotype in fibroblasts, contributing to disruption of critical matrix–cardiomyocyte interactions required for cell survival [73]. Sixth, IL-1-driven matrix degradation may ultimately activate fibroblast-mediated matrix protein synthesis, resulting in accentuated fibrosis [75] through increased expression of fibrogenic growth factors. Seventh, IL-1 may increase arterial stiffness [76] and microvascular inflammation, thus contributing to the pathogenesis of HFpEF. Finally, in heart failure associated with autoimmune myocarditis, the effects of IL-1 may involve dendritic cell activation and subsequent stimulation of autoreactive CD4+ T cells [77].

Targeting the IL-1 System in Human Heart Failure Patients

In the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial, treatment of patients with prior myocardial infarction and evidence of active inflammation (suggested by elevated high sensitivity C-reactive protein (hsCRP)) with the anti-IL1β monoclonal antibody canakinumab had modest favorable effects, reducing the risk of the composite endpoint (non-fatal myocardial infarction, non-fatal stroke or death) by 15% in comparison with standard treatment [78]. The study supported the role of IL-1β in the pathogenesis of atherothrombotic disease and also generated observations that may be important in understanding and treating heart failure. A pre-specified exploratory analysis of the CANTOS data showed that IL-1β inhibition reduced the rate of heart failure hospitalizations or heart failure–related death in a dose-dependent manner [79]. Although the CANTOS trial was not designed to examine the effectiveness of IL-1β targeting in heart failure, the findings are consistent with animal model experiments and suggest that canakinumab may have therapeutic benefit in subsets of heart failure patients. Animal model studies also support protective actions of gevokizumab, another anti-IL-1β antibody, in patients with post-infarction heart failure [67]. In addition, other smaller studies further support this concept. In two small clinical studies in HFpEF patients, anakinra treatment improved indicators of systolic function [80]. In a small group of patients with HFpEF and elevated hsCRP, treatment with anakinra reduced NT-proBNP, but failed to improve indicators of cardiorespiratory fitness [81]. Moreover, in patients with rheumatoid arthritis, treatment with anakinra improved indicators of left ventricular and vascular function [76, 82]. Thus, IL-1 inhibition may hold promise as therapy for subpopulations of heart failure patients exhibiting prominent pro-inflammatory activation.

IL-6

IL-6 is the prototypical member of the gp130 cytokine family of cytokines that also includes several other cytokines that have been implicated in the pathogenesis of cardiovascular diseases, such as IL-11, leukemia inhibitory factor (LIF), cardiotoxin-1, and oncostatin-M. These cytokines transduce signals through the common signaling receptor subunit gp130 [83], activating Janus kinases and triggering STAT3 phosphorylation.
Expression and Role of IL-6 in Heart Failure

IL-6 is consistently upregulated in experimental models of cardiac injury and heart failure regardless of the underlying etiology, and is expressed by cardiomyocytes, infiltrating mononuclear cells, and fibroblasts [30, 84–86]. Moreover, in pressure-overloaded hearts, IL-6 induction is accompanied by upregulation of the IL-6 receptor (IL-6Rα) [86]. Increased IL-6 expression may reflect the stimulatory effects of neurohumoral pathways, Toll-like receptor (TLR) agonists, or other pro-inflammatory cytokines (such as TNF-α and IL-1) on myocardial cells, or infiltrating leukocytes. During heart failure progression, negative regulatory mechanisms may be activated to restrain expression of IL-6 and other pro-inflammatory cytokines. Degradation of IL-6 mRNA by the RNase regnase-1 has been suggested as a mechanism restraining IL-6 expression and pro-inflammatory actions in the pressure-overloaded myocardium [87]. Although several clinical studies have demonstrated that failing hearts have increased myocardial IL-6 expression in comparison with non-failing myocardium [88], other investigations failed to show increased IL-6 synthesis in heart failure [89], but reported increased levels of downstream components of the IL-6 signaling cascade, such as gp130. The conflicting findings may reflect sampling at different stages of the disease, study of different subsets of heart failure patients, or activation of the IL-6/IL-6R axis [90] in rejected donor hearts, typically used as controls in many studies.

Experimental studies on the role of IL-6 in heart failure have produced conflicting findings, dependent on the model, the pathophysiologic context, and the type of interventions used to study the effects of IL-6 signaling. The bulk of the evidence suggests that the effects of IL-6 signaling in the failing heart are primarily pro-inflammatory and may accentuate dysfunction. Persistent gp130/STAT3 signaling enhanced inflammation in remodeling infarcted hearts [91]. Moreover, in the pressure-overloaded myocardium, genetic loss of IL6 improved cardiac function and attenuated hypertrophy through actions attributed to abrogation of CaMKII-dependent effects on cardiomyocytes [92]. However, other investigations using similar genetic approaches found no significant effects of IL6 deletion on the pressure-overloaded heart [93]. Pharmacologic blockade of IL-6 through administration of an anti-IL6R antibody attenuated dilation and improved function in a model of post-infarction heart failure [94].

The Pleiotropic Actions of IL-6 in the Failing Heart: The Impact of Cell-Specific Effects and Trans-Signaling

IL-6 is notorious for its pleiotropic actions on many different cell types involved in heart failure, including macrophages, lymphocytes, cardiomyocytes, fibroblasts, and vascular cells. Moreover, the concept of IL-6 trans-signaling contributes an additional layer of complexity to IL-6-mediated actions. Classic IL-6 signaling involves binding of the cytokine to the IL-6R on the cell surface, and subsequent association of the IL-6/IL-6R complex with gp130, which dimerizes and initiates signaling. However, IL-6 can also signal in the absence of cell surface IL-6R. A Disintegrin and Metalloprotease (ADAM) proteases can cleave IL-6R from the cells, generating soluble IL-6R (sIL-6R), which may associate with IL-6, stimulating gp130 signaling on cells that do not express IL-6R on their surface [95]. This mechanism called “trans-signaling” significantly expands the cellular repertoire of IL-6 and complicates interpretation of its cellular actions (Fig. 2) [83]. Unfortunately, very little is known regarding the relative in vivo role of classic and trans IL-6 signaling in the failing heart.

In heart failure, IL-6 has important modulatory effects on several different cell types. In cardiomyocytes, IL-6 exerts negative inotropic effects [96] and promotes a hypertrophic response [97–99] through the gp130/STAT3 pathway, but may also exert protective actions, mediated through preservation of mitochondrial function [100]. In fibroblasts, IL-6 promotes proliferation and stimulates ECM synthesis [101–103]. The combined effects of IL-6 on cardiomyocytes and fibroblasts may play an important role in the pathogenesis of HfPEF. In experimental mouse studies, infusion of IL-6 caused concentric hypertrophy and fibrosis, and increased myocardial stiffness [97]. IL-6 also has potent modulatory effects on macrophages and lymphocytes. Both pro- and anti-inflammatory effects of IL-6 have been reported [104–107]; trans-signaling has been suggested to exert pro-inflammatory actions, whereas canonical IL-6 signaling may be anti-inflammatory [108]. The in vivo role of IL-6 in inflammation is likely dependent on the relative contribution of macrophage and lymphocyte subsets, and on the relative role of classic versus trans-signaling in each specific inflammatory condition. In the absence of cell-specific dissection in vivo, it is impossible to define the role of inflammatory signaling in mediating the in vivo effects of IL-6 in failing hearts.

Targeting IL-6 in Human Heart Failure

Extensive evidence suggests that IL-6 plays a crucial role in the post-inflammatory hepatic acute phase response and is implicated in autoimmunity. Based on this evidence, IL-6 has been considered an attractive therapeutic target in many conditions associated with inflammation. The IL-6 receptor neutralizing antibody tocilizumab has been approved as effective therapy for patients with moderate to severe rheumatoid arthritis and temporal arteritis, and for the treatment of the cytokine release syndrome associated with CAR-T cell therapies. Experimental evidence demonstrating involvement of IL-6 signaling in the pathogenesis of heart failure suggests that treatment with tocilizumab may also be effective in heart failure patients. However, clinical studies supporting this
notion are lacking. In patients with rheumatoid arthritis in the absence of cardiovascular disease, tocilizumab reduced the circulating levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) [109]; this finding may reflect cardioprotective actions that may attenuate heart failure development. A phase II clinical trial tested the effectiveness of tocilizumab in reducing ischemic myocardial injury in acute coronary syndromes. Classically, IL-6 signals through binding to the IL-6 receptor (IL-6R) which in turn associates with the dimerized gp130 receptor subunit gp130 to form a receptor complex that activates Janus kinases and triggers STAT3 phosphorylation. Cells lacking the IL-6R may also be affected by IL-6 through trans-signaling. ADAM proteases can cleave IL-6R from cell surface, generating soluble IL-6R (sIL-6R), which may associate with IL-6, stimulating gp130/STAT3 signaling on cells lacking IL-6R. While classic IL-6 signaling may be anti-inflammatory, trans-signaling has been suggested to exert pro-inflammatory actions. The relative contributions of canonical and trans IL-6 signaling in heart failure have not been systematically studied. This cartoon was designed using Servier Medical Art (https://smart.servier.com/).

It should be noted that the use of anti-IL-6 therapeutics is complicated by the classic versus trans-signaling actions of the cytokine. Anti-IL-6R antibodies block all modes of IL-6 signaling, whereas soluble gp130 selectively inhibits IL-6 trans-signaling by binding to the IL-6–sIL-6R complex. The effects of various IL-6 targeting strategies on the failing heart have not been systematically investigated.

CCL2 and the Chemokines

Chemokines are small (8–12 kDa) chemotactic cytokines that regulate cell migration and positioning in development, homeostasis, and inflammation [112]. On a structural basis,
chemokines can be subclassified into four subfamilies: the XC, CC, CXC, and CX3C chemokines. From a functional perspective, chemokines can be “homeostatic” (constitutively expressed in certain tissues and involved in basal leukocyte trafficking and formation of lymphoid organs), “inflammatory” (members inducible following injury with effects in leukocyte recruitment and activation) [113–115], or may exhibit both homeostatic and inflammatory roles. The inflammatory CC chemokine CCL2/MCP-1 is the best-studied member of the family in heart failure and has been suggested as a therapeutic target in conditions associated with myocardial injury and adverse remodeling [116].

Expression and Role of CCL2 in Failing Hearts

CCL2 is markedly and consistently upregulated in experimental models of cardiac injury, remodeling and heart failure [19, 57, 117–119]. In infarcted and failing hearts, CCL2 has been localized in endothelial cells [117], vascular smooth muscle cells [120], mononuclear cells [17], and cardiomyocytes [119]; its induction may involve activation of TLR signaling, neurohumoral cascades, or pro-inflammatory cytokine-mediated pathways [115]. Studies in human patients also demonstrated CCL2 upregulation in failing hearts. CCL2 was overexpressed in myocardial samples from patients with ischemic [14], dilated [121], or hypertrophic cardiomyopathy [122].

Extensive experimental evidence suggests that CCL2 contributes to adverse remodeling, dysfunction, and fibrosis in models of infarctive and non-infarctive heart failure (Table 1). In models of myocardial infarction, CCL2 deletion and anti-CCL2 gene therapy improved adverse remodeling [124], at the expense of delayed phagocytosis of dead cardiomyocytes with granulation tissue [19]. In a model of ischemic fibrotic cardiomyopathy induced through brief repetitive ischemia followed by reperfusion, CCL2 contributed to macrophage recruitment, fibrotic remodeling, and systolic dysfunction [17]. Moreover, in a model of left ventricular pressure overload, CCL2 neutralization attenuated diastolic dysfunction, reducing fibrosis [120]. Clinical studies have also generated associative data consistent with an important role of CCL2 in heart failure. In HFrEF patients, high circulating CCL2 levels were associated with more severe symptoms and worse systolic dysfunction [130]. Moreover, in patients with advanced heart failure, high circulating levels of CCL2 were associated with increased mortality [131].

What Is the Cellular Basis for the Effects of CCL2 on Cardiac Remodeling and Dysfunction?

Immune cells are the most likely major cellular targets of CCL2 in failing hearts. As an inducible inflammatory CC chemokine, CCL2 is markedly upregulated following injury, binds to proteoglycans on the endothelium or the ECM, and promotes recruitment of pro-inflammatory CCR2+ monocytes. In the infarcted and remodeling myocardium, CCR2+ monocytes may promote injury and exacerbate dysfunction by secreting pro-inflammatory cytokines and matrix-degrading proteases. CCL2-driven pro-inflammatory signaling may accentuate cardiomyocyte death; disruption of the CCL2/CCR2 axis in experimental models of myocardial infarction was reported to reduce infarct size in many [132–135] but not in all studies [19].

CCL2 may also exert potent fibrogenic actions on the remodeling myocardium [17]. CCL2-mediated fibrosis has been attributed primarily to recruitment and activation of monocytes and macrophages, resulting in increased synthesis of fibrogenic mediators, such as TGF-β and osteopontin [17, 19, 136]. Whether CCL2 may also exert direct fibrogenic actions through effects on resident cardiac fibroblasts or their progenitors remains controversial. Although CCL2 has been reported to stimulate pro-fibrotic signaling in skin, liver, and lung fibroblasts [137–139], in cardiac fibroblasts, CCL2 did not affect matrix gene synthesis or proliferative activity [17]. It has also been suggested that CCL2 may exert fibrogenic actions through recruitment of circulating fibroblast progenitors [126, 140]. However, the evidence supporting this notion is associative, based on colocalization of relatively non-specific hematopoietic cell and fibroblast markers in the same cells. Lineage tracing studies have consistently demonstrated that most activated fibroblasts in failing hearts are derived from resident fibroblast populations, and not from circulating hematopoietic cells [141–143]. Thus, the potential role of CCL2-mediated recruitment of fibroblast progenitors in cardiac fibrosis remains unclear [144].

It has also been suggested that CCL2 may exert direct actions on cardiomyocytes, increasing injury-associated death and promoting dysfunction. Some studies have suggested that CCL2 may promote cardiomyocyte apoptosis through induction of the ribonuclease monocyte chemoattractant protein-1-induced protein (MCPIP, originally proposed to function as a transcription factor), also known as regnase-1 [145, 146]. However, regnase-1/MCPIP can be induced by a wide range of inflammatory mediators, and is known to restrain inflammation by degrading cytokine RNAs in immune and non-immune cells [147]. Although the bulk of the experimental evidence suggests that CCL2 contributes to adverse remodeling (while playing a role in cardiac repair), some studies using CCL2-overexpressing mice have suggested cardioprotective actions of CCL2 in ischemia/reperfusion, mediated through effects that may involve attenuation of oxidative stress [148]. These findings may reflect the consequences of baseline alterations in the cardiac microenvironment in CCL2-overexpressing mice undergoing ischemia protocols, rather than direct protective actions of CCL2 on cardiomyocytes.
CCL2 as a Therapeutic Target in Heart Failure

Considering the extensive evidence suggesting a causative role for CCL2 in cardiac remodeling and dysfunction, antagonism of the CCL2/CCR2 axis holds promise as heart failure therapy. Other CC chemokines may also be involved in recruitment of pro-inflammatory leukocytes; thus, combined targeting of several CC chemokine receptors may increase the effectiveness of the approach. Despite decades of experimental work on the biology of the chemokines, implementation of chemokine-targeting therapeutics in inflammatory conditions remains at an early stage. In a phase II clinical trial, treatment with an anti-CCR2 antibody failed to improve symptoms in patients with rheumatoid arthritis [149]. Another phase II trial using the dual CCR2/CCR5 inhibitor cenicriviroc in patients with non-alcoholic steatohepatitis showed promise, suggesting attenuation of inflammation-driven fibrosis [150]. The effectiveness of CC chemokine targeting in human patients with heart failure has not been tested. Despite the established role of the CCL2/CCR2 axis in cardiac remodeling, several concerns are raised regarding the potential effects of CC chemokine inhibition. First, macrophages do not exert solely pro-inflammatory actions, but also serve to downregulate inflammation and to stimulate angiogenesis. Experimental studies have suggested that CCL2 may play a role in arteriogenesis [151], a process that may be important for preservation of myocardial perfusion in...
patients with heart failure. Targeting CCR2 may not selectively inhibit recruitment of pro-inflammatory macrophages, but may also perturb downstream inflammatory responses that recruit protective leukocyte subsets in the remodeling myocardium. Second, use of dual CC chemokine inhibitors to target inflammation in heart failure may also reduce recruitment of lymphocyte subpopulations involved in suppression of inflammation, such as regulatory T cells (Tregs) [152].

**The Challenges of Clinical Translation**

Therapeutic translation is always challenging, especially when dealing with a pathophysiologically heterogeneous condition, such as heart failure. Despite the promising experimental findings in animal models, targeting pro-inflammatory chemokines and cytokines has not yet produced therapeutic benefit in patients with heart failure. Several major challenges have hampered therapeutic translation. First, documentation of clinical benefits in human heart failure populations requires well-designed and very expensive clinical trials with long follow-up. Thus, the pace of testing candidate agents in clinical trials is predictably slow. Second, animal models are inherently suboptimal tools for prediction of therapeutic efficacy. The strength of animal model studies lies in the provision of cell biological insights using reductionist approaches and standardized protocols. No animal model can recapitulate the pathophysiologic heterogeneity of human heart failure. Thus, a major priority in clinical heart failure research is the pathophysiologic stratification of human patient populations and the identification of patient subsets with excessive or dysregulated inflammatory responses. Use of inflammatory biomarkers and imaging strategies may contribute to identification of patients that may benefit from targeted cytokine therapeutics [153]. Third, the need for chronic administration of cytokine or chemokine inhibitors to delay progression of heart failure is a major concern. Pro-inflammatory signaling plays an important role in the defense against infections, in reparative responses to injury, and in control of tumors. Moreover, some members of the cytokine family have been suggested to exert important protective actions on cardiomyocytes under conditions of stress. Considering the perils of chronic administration of anti-cytokine therapeutics, it may be preferable to focus on clinical settings associated with rapid inflammation-driven cardiac remodeling, such as post-infarction heart failure [154] or acute myocarditis. In these conditions, brief cytokine inhibition may have lasting effects on the remodeling process, protecting from the development of heart failure.

**Conclusions**

Over the last 30 years, experimental and clinical studies have greatly contributed to our understanding of the role of inflammation in the pathogenesis of heart failure. Despite early disappointments in clinical translation, targeting inflammatory mediators remains a promising and attractive direction in heart failure therapeutics. Successful implementation of cytokine targeting approaches in heart failure patients will require dissection of specific pro-inflammatory pathways with a critical role in dysfunction and progression of adverse remodeling, and identification of patient subpopulations with dysregulated or overactive inflammatory responses that may derive maximal benefit from targeted cytokine or chemokine inhibition.

**References**

1. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124:1598–617. https://doi.org/10.1161/CIRCRESAHA.119.313572.
2. Braunwald E. Heart disease. A textbook of cardiovascular medicine. 4th Ed. Philadelphia: WB Saunders; 1992.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282–9. https://doi.org/10.1161/01.cir.98.21.2282.
4. Dick SA, Epelman S. Chronic heart failure and inflammation: what do we really know? Circ Res. 2016;119:159–76. https://doi.org/10.1161/CIRCRESAHA.116.308010.
5. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121:803–18. https://doi.org/10.1161/CIRCRESAHA.117.310221.
6. Wilson HM, Cheyne L, Brown PAJ, Kerr K, Hannah A, Srinivasan J, et al. Characterization of the myocardial inflammatory response in acute stress-induced (Takotsubo) cardiomyopathy. JACC Basic Transl Sci. 2018;3:766–78. https://doi.org/10.1016/j.jacbts.2018.08.006.
7. Scally C, Abbas H, Ahearn T, Srinivasan J, Mezincescu A, Rudd A, et al. Myocardial and systemic inflammation in acute stress-induced (Takotsubo) cardiomyopathy. Circulation. 2019;139:1581–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037975.

8. Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, et al. Takotsubo cardiomyopathy in COVID-19. J Am Coll Cardiol. 2020;76:628–9. https://doi.org/10.1016/j.jacc.2020.05.068.

9. Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, et al. Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic. JAMA Netw Open. 2020;3:e2014780. https://doi.org/10.1001/jamanetworkopen.2020.14780.

10. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated nitric oxide. Science. 1992;257:387–90.

11. Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006–14. https://doi.org/10.1002/ejhf.414.

12. Abernethy A, Raza S, Sun JLI, Anstrom KJ, Tracy R, Steiner J, et al. Pro-inflammatory biomarkers in stable versus acutely decompensated heart failure with preserved ejection fraction. J Am Heart Assoc. 2018;7. https://doi.org/10.1161/JAHA.117.007385.

13. Chirinos JA, Olenko A, Zhao L, Basso MD, Cvicj ME, Li Z, et al. Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2020;75:1281–95. https://doi.org/10.1016/j.jacc.2019.12.069.

14. Frangogiannis NG, Shimoni S, Chang SM, Ren G, Shan K, Aggelis C, et al. Evidence for an active inflammatory process in the hypertrophied human myocardium. Am J Pathol. 2002;160:1425–33.

15. Sun M, Chen M, Dawood F, Zuraw ska U, Li JY, Parker T, et al. CCL2/monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha in the pathogenesis of ischemic cardiomyopathy. J Immunol Res. 2018;2018:5301548.

16. Frangogiannis NG, Kapadia S, Lee J, Torre-Amione G, Birdssall HH, Ma TS, Mann DL. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxic administration. J Clin Invest. 1995;96:1042–52. https://doi.org/10.1172/JCI18090.

17. Frangogiannis NG, Kapadia SR, Oral H, Lee J, Nakanou M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187–95. https://doi.org/10.1161/01.res.81.2.187.

18. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–11.

19. Shioi T, Matsunori A, Sasayama S. Persistent expression of cytokine in the chronic stage of viral myocarditis in mice. Circulation. 1996;94:2930–7.

20. Frangogiannis NG, Lindsey ML, Michael LH, Youker KA, Bressler RB, Mendoza LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98:699–710.

21. Janczewski AM, Kadokami T, Lemster B, Frye CS, McTiernan CF, Feldman AM. Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol. 2003;284:H960–9. https://doi.org/10.1152/ajpheart.0718.2001.

22. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375–81.

23. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest. 1992;90:389–98. https://doi.org/10.1172/JCI115873.

24. Jobe LJ, Melendez GC, Levick SP, et al. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. Am J Physiol Heart Circ Physiol. 2009;297:H1462–8. https://doi.org/10.1152/ajpheart.00442.2009.

25. Berry MF, Woo YJ, Piroli TJ, Bish LT, Moise MA, Burdick JW, et al. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. J Heart Lung Transplant. 2004;23:1061–8. https://doi.org/10.1016/j.healun.2004.06.021.

26. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625–31. https://doi.org/10.1161/CIRCULATIONAHA.107.759191.

27. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993;92:2303–12.

28. Haudek SB, Taffet GE, Schneider MD, Mann DL. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest. 2007;117:2692–701.
39. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119:1386–97.

40. Sanders DB, Larson DF, Hunter K, Gorman M, Yang B. Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes. Perfusion. 2001;16:67–74. https://doi.org/10.1077/026765910101600110.

41. Sivasubramanian N, Coker ML, Kurremeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104:826–31. https://doi.org/10.1161/hc401.003154.

42. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A. 2000;97:12746–51. https://doi.org/10.1073/pnas.97.23.12746.

43. Mark KS, Trickler WJ, Miller DW. Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther. 2001;297:1051–8.

44. Mattila P, Majuri ML, Mattila PS, Renkonen R. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase C activation. Scand J Immunol. 1992;36:159–65. https://doi.org/10.1111/j.1365-3083.1992.tb05087.x.

45. Panpathanasou S, Rickelt S, Soriano ME, Schips TG, Maier HJ, Davos CH, et al. Tumor necrosis factor-alpha confers cardioprotection through ectopic expression of keratin K8 and K18. Nat Med. 2015;21:1076–84. https://doi.org/10.1038/nm.3925.

46. Rathi SS, Xu YJ, Dhalla NS. Mechanism of cardioprotective action of TNF-alpha in the isolated rat heart. Exp Clin Cardiol. 2002;7:146–50.

47. Lacerda L, McCarthy J, Mungly SF, et al. TNF alpha protects cardiac mitochondria independently of its cell surface receptors. Basic Res Cardiol. 2010;105:751–62. https://doi.org/10.1007/s00395-010-0113-4.

48. Deswal A, Bozkurt B, Seta Y, Marchetti C, Kron J, van Tassel BW, Dinarello CA. Interleukin-1 and the Inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126:1260–80. https://doi.org/10.1161/CIRCRESAHA.120.315937.

49. Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol. 2004;164:665–77.

50. Shioi T, Matsumori A, Kihara Y, Inoko M, Ono K, Iwanaga Y, et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemotactic protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 1997;81:664–71.

51. Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis NG. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol. 2009;131:471–81.

52. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jagabi H, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol. 2013;98:462–72. https://doi.org/10.1113/expphysiol.2012.068338.

53. Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One. 2014;9:e104771. https://doi.org/10.1371/journal.pone.0104771.

54. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol. 1998;30:215–23.

55. Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, et al. Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca(2+)/calmodulin-dependent protein kinase II delta signaling in cardiomyocytes are essential for adverse cardiac remodeling. Circulation. 2018;138:2530–44. https://doi.org/10.1161/CIRCULATIONAHA.118.036421.

56. Mezzaroma E, Toldo S, Forkas D, Seropian IM, van Tassel BW, Salloum FN, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A. 2011;108:19725–30.

57. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594–604.

58. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. Anakintra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117:2670–83.

59. Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, Wu M, et al. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol. 2010;643:247–53. https://doi.org/10.1016/j.ejphar.2010.06.024.

60. Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dumesnil A, Lejeune A, et al. The IL-1beta antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure. JACC Basic Transl Sci. 2017;2:418–30. https://doi.org/10.1016/j.jacbts.2017.06.005.

61. Honsho S, Nishikawa S, Amano K, Zen K, Adachi Y, Kishita E, et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ Res. 2009;105:1149–58. https://doi.org/10.1161/CIRCRESAHA.109.208199.
function in cardiomyocytes. Cardiovasc Res. 2006;69:164–77. https://doi.org/10.1016/j.cardiores.2005.08.017.

101. Chou CH, Hung CS, Liao CW, Wei LH, Chen CW, Shun CT, et al. IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis. Cardiovasc Res. 2018;114:690–702. https://doi.org/10.1093/cvr/cvy013.

102. Leicht M, Briest W, Zimmer HG. Regulation of norepinephrine-induced proliferation in cardiac fibroblasts by interleukin-6 and p42/p44 mitogen activated protein kinase. Mol Cell Biochem. 2003;243:65–72. https://doi.org/10.1023/a:1021655023870.

103. Mir SA, Chatterjee A, Mitra A, Pathak K, Mahata SK, Sarkar S. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J Biol Chem. 2012;287:2666–77. https://doi.org/10.1074/jbc.M111.246173.

104. Mitani H, Katayama N, Araki H, Ohishi K, Kobayashi K, Suzuki H, et al. Activity of interleukin 6 in the different myeloid cell lineages of macrophages and dendritic cells. Br J Haematol. 2000;109:288–95. https://doi.org/10.1046/j.1365-2141.2000.02020.x.

105. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol. 2014;15:423–30. https://doi.org/10.1038/nii.2865.

106. Sackett SD, Otto T, Mohs A, Sander LE, Strauch S, Streitz KL, et al. Myeloid cells require gp130 signaling for protective anti-inflammatory functions during sepsis. FASEB J. 2019;33:6035–44. https://doi.org/10.1096/fj.201802118R.

107. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 1813;2011:878–88. https://doi.org/10.1016/j.bbamer.2011.01.034.

108. Kraakman MJ, Kammoun HL, Allen TL, Deswaert CE, Henstridge DC, Estevez E, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21:403–16. https://doi.org/10.1016/j.cmet.2015.02.006.

109. Yokoe I, Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Kitamura N, et al. Impact of tocilizumab on N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis without cardiac symptoms. Scand J Rheumatol. 2018;47:364–70. https://doi.org/10.1080/03009742.2017.1418424.

110. Cleveland O, Kunszt G, Brattle M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. 2016;37:2406–13. https://doi.org/10.1093/eurheartj/ehw171.

111. Cleveland O, Ueland T, Kunszt G, Brattle M, Ynesteem A, Broch K, et al. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IL-10 and MIP-1 beta in non-ST-elevation myocardial infarction. Int J Cardiol. 2018;271:1–7. https://doi.org/10.1016/j.ijcard.2018.04.136.

112. Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7. https://doi.org/10.1101/cshperspect.a016303.

113. Clark-Lewis I, Kim KS, Rajaratnam K, Gong JH, Dewald B, Moser B, et al. Structure–activity relationships of chemokines. J Leukoc Biol. 1995;57:703–11.

114. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol. 1999;19:1–47.

115. Chen B, Frangogiannis NG. Chemokines in myocardial infarction. J Cardiovasc Transl Res. 2020. https://doi.org/10.1007/s12265-020-10006-7.

116. Xia Y, Frangogiannis NG. MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy. Inflamm Allergy Drug Targets. 2007;6:101–7.

117. Kumar AG, Ballantyne CM, Michael LH, Kukielska GL, Youker KA, Lindsey ML, et al. Induction of monocyte chemotactant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation. 1997;95:693–700.

118. Dewald O, Frangogiannis NG, Zoerlein M, Duerr GD, Klemm C, Knueffermann P, et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc Natl Acad Sci U S A. 2003;100:2700–5.

119. Behr TM, Wang X, Aiyar N, Coatey MV, Li X, Koster P, et al. Monocyte chemotactant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation. 2000;102:1315–22.

120. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739–45.

121. Lehmann MH, Kuhnert H, Muller S, Sigusch HH. Monocyte chemotactant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. Cytochrome. 1998;10:739–46.

122. Iwasaki J, Nakamura K, Matsubara H, Nakamura Y, Nishii N, Banba K, et al. Relationship between circulating levels of monocyte chemotactant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol. 2009;18:317–22. https://doi.org/10.1016/j.carpath.2008.12.004.

123. Patel B, Bansal SS, Ismaili MA, Hamid T, Rokosh G, Mack M, et al. CCR2(+) monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload. JACC Basic Transl Sci. 2018;3:230–44. https://doi.org/10.1016/j.jacbts.2017.12.006.

124. Hayashidani S, Tsutsui H, Shiomi T, Ikeuchi M, Matsusaka H, Suematsu N, et al. Anti-monocyte chemotactant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108:2134–40.

125. Bajpai G, Bredermeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, et al. Tissue resident CCR2− and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res. 2019;124:263–76. https://doi.org/10.1161/CIRCRESAHA.118.314028.

126. Haudek SB, Cheng J, Du J, et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2010;49:499–507.

127. Trial J, Heredia CP, Taffet GE, Entman ML, Cieslik KA. Dissecting the role of myeloid and mesenchymal fibroblasts in age-dependent cardiac fibrosis. Basic Res Cardiol. 2017;112:34. https://doi.org/10.1007/s00395-017-0623-4.

128. Tan X, Hu L, Shu Z, Chen L, Li X, Lu M, et al. Role of CCR2 in the development of streptozotocin-treated diabetic cardiomyopathy. Diabetes. 2019;68:2063–73. https://doi.org/10.2337/db18-1231.

129. Kolattukudy PE, Quach T, Bergese S, Breckenridge S, Hensley J, Altschuld R, et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol. 1998;152:101–11.

130. Stumpf C, Lehrner C, Raaz D, Vilmaz A, Anger T, Daniel WG, et al. Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure. Heart. 2008;94:65–70. https://doi.org/10.1136/hrt.2007.115006.

131. Hohensinner PJ, Rychli K, Zorn G, Hülsmann M, Berger R, Mörtl J, et al. Structure and function in cardiomyocytes. Cardiovasc Res. 2006;69:164–77. https://doi.org/10.1016/j.cardiores.2005.08.017.
